Yang Dajun, Ph.D.,is the Co-Founder, Chairman of the Board, and Chief Executive Officer of Ascentage Pharma. Dr. Yang has dedicated his career to the research on apoptosis and innovative drug R&D for nearly 30 years. In 2009, he co-founded Ascentage Pharma and made major breakthroughs in the research of development of precision drugs targeting apoptosis and autophagy dual-channel regulation. Ascentage Pharma is the only company in the world that researches and develops innovative drugs targeting all of these pathways. Ascentage Pharma currently has eight potential “First-in-class” or “Best-in-class” innovative drug candidates in Phase I/II clinical developments in China, the United States, Australia and Europe. Dr. Yang has undertaken nearly ten National Science and Technology Major Projects such as the National High-tech R&D Program (the “863 Program”) and the Major Innovative Drug Developments program. Dr. Yang was the president of Chinese Biopharmaceutical Association-USA from 2005 to 2006 and has concurrently served as professor and Ph.D. supervisor at Sun Yat-sen University Cancer Center, director of the Drug R&D Specialty Committee of China Pharmaceutical Innovation and Research Development Association, and part-time researcher in Pharmaceutical Innovations at Shanghai Institute of Materia Medica, Chinese Academy of Sciences.